Piper Jaffray Maintains Overweight Rating And PT At $17 On Omnicell (OMCL)

Piper Jaffray maintained its Overweight rating on Omnicell OMCL in a research report published today. It also left its price target unchanged at $17. In the report, Piper Jaffray states, "The company reported a penny upside on EPS and in-line revenues by continued expansion in gross margins of both product and service segments, and launched multiple products to increase their competitive advantage. With 41% of the orders coming from new customers and half of them from competitive replacements, we believe the company is gaining market share at a healthy rate. With multiple opportunities for revenue and earnings growth, we like the stock at this valuation. Maintain Overweight, $17 target." In yesterday's trading, Omnicell's shares were up 1.5% to close the day at $15.61. In today's pre-market trading, its shares traded at $15.80, up 1.22% on Monday's closing value.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsHealth CareHealth Care TechnologyomnicellPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!